Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
3.7
4.7
Journals
Biomedicines
Special Issues
Non-invasive Biomarkers in Biologic Therapy for Oncology and Chronic Inflammation
share announcement

Non-invasive Biomarkers in Biologic Therapy for Oncology and Chronic Inflammation

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Cancer Biology and Oncology".

Deadline for manuscript submissions: closed (31 January 2023) | Viewed by 5531

Special Issue Editor

Dr. Silvia Vidal

E-Mail Website
Guest Editor
Department of Immunology, Institut de Recerca, Hospital de la Santa Creu I Sant Pau, Barcelona, Spain
Interests: inflammation; immunotherapy; platelets

Special Issue Information

Dear Colleagues,

There is a growing interest in finding accurate non-invasive biomarkers for the identification of patients who might benefit from biologic therapy. Although this therapy has dramatically changed clinical practice, its benefits are curbed by the heterogeneous response of patients. It is therefore of utmost importance to find markers that predict the patient response to biologic therapy. To achieve this aspect of personalized medicine, one major step forward may be finding non-invasive biomarkers in human fluids (blood, saliva, urine, pleural fluid, tears, etc.). Thanks to technological breakthroughs, newly discovered biomarkers might be included in large validation studies in the near future. However, challenges and complexities in the path of translating the discovered biomarkers from the research laboratory to the clinical setting remain and would have to be addressed before including them in clinical practice.

In this Special Issue, experts in the field of cancer and inflammation will describe the most recent approaches (liquid biopsy, high throughput omics, extracellular vesicles, functional assays, etc.) to find non-invasive biomarkers of response to biologic therapy. This will include research articles using different sources of samples to apply these approaches.

Dr. Silvia Vidal
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • immunotherapy
  • personalized medicine
  • prognosis markers

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

19 pages, 19425 KiB  
Article
Urinary ACE Phenotyping as a Research and Diagnostic Tool: Identification of Sex-Dependent ACE Immunoreactivity
by Alexander J. Kozuch, Pavel A. Petukhov, Miklos Fagyas, Isolda A. Popova, Matthew O. Lindeblad, Alexander P. Bobkov, Armais A. Kamalov, Attila Toth, Steven M. Dudek and Sergei M. Danilov
Biomedicines 2023, 11(3), 953; https://doi.org/10.3390/biomedicines11030953 - 20 Mar 2023
Cited by 2 | Viewed by 1622
Abstract
Background: Angiotensin-converting enzyme (ACE) is highly expressed in renal proximal tubules, but ACE activity/levels in the urine are at least 100-fold lower than in the blood. Decreased proximal tubular ACE has been associated with renal tubular damage in both animal models and clinical [...] Read more.
Background: Angiotensin-converting enzyme (ACE) is highly expressed in renal proximal tubules, but ACE activity/levels in the urine are at least 100-fold lower than in the blood. Decreased proximal tubular ACE has been associated with renal tubular damage in both animal models and clinical studies. Because ACE is shed into urine primarily from proximal tubule epithelial cells, its urinary ACE measurement may be useful as an index of tubular damage. Objective and Methodology: We applied our novel approach—ACE phenotyping—to characterize urinary ACE in volunteer subjects. ACE phenotyping includes (1) determination of ACE activity using two substrates (ZPHL and HHL); (2) calculation of the ratio of hydrolysis of the two substrates (ZPHL/HHL ratio); (3) quantification of ACE immunoreactive protein levels; and (4) fine mapping of local ACE conformation with mAbs to ACE. Principal findings: In normal volunteers, urinary ACE activity was 140-fold less than in corresponding plasma/serum samples and did not differ between males and females. However, urinary ACE immunoreactivity (normalized binding of 25 mAbs to different epitopes) was strongly sex-dependent for the several mAbs tested, an observation likely explained by differences in tissue ACE glycosylation/sialylation between males and females. Urinary ACE phenotyping also allowed the identification of ACE outliers. In addition, daily variability of urinary ACE has potential utility as a feedback marker for dieting individuals pursuing weight loss. Conclusions/Significance: Urinary ACE phenotyping is a promising new approach with potential clinical significance to advance precision medicine screening techniques. Full article
(This article belongs to the Special Issue Non-invasive Biomarkers in Biologic Therapy for Oncology and Chronic Inflammation)
►▼ Show Figures

Figure 1

Review

Jump to: Research

29 pages, 549 KiB  
Review
Challenges and the Evolving Landscape of Assessing Blood-Based PD-L1 Expression as a Biomarker for Anti-PD-(L)1 Immunotherapy
by Tao Wang, Desirée Denman, Silvia M. Bacot and Gerald M. Feldman
Biomedicines 2022, 10(5), 1181; https://doi.org/10.3390/biomedicines10051181 - 20 May 2022
Cited by 9 | Viewed by 3367
Abstract
While promising, PD-L1 expression on tumor tissues as assessed by immunohistochemistry has been shown to be an imperfect biomarker that only applies to a limited number of cancers, whereas many patients with PD-L1-negative tumors still respond to anti-PD-(L)1 immunotherapy. Recent studies using patient [...] Read more.
While promising, PD-L1 expression on tumor tissues as assessed by immunohistochemistry has been shown to be an imperfect biomarker that only applies to a limited number of cancers, whereas many patients with PD-L1-negative tumors still respond to anti-PD-(L)1 immunotherapy. Recent studies using patient blood samples to assess immunotherapeutic responsiveness suggests a promising approach to the identification of novel and/or improved biomarkers for anti-PD-(L)1 immunotherapy. In this review, we discuss the advances in our evolving understanding of the regulation and function of PD-L1 expression, which is the foundation for developing blood-based PD-L1 as a biomarker for anti-PD-(L)1 immunotherapy. We further discuss current knowledge and clinical study results for biomarker identification using PD-L1 expression on tumor and immune cells, exosomes, and soluble forms of PD-L1 in the peripheral blood. Finally, we discuss key challenges for the successful development of the potential use of blood-based PD-L1 as a biomarker for anti-PD-(L)1 immunotherapy. Full article
(This article belongs to the Special Issue Non-invasive Biomarkers in Biologic Therapy for Oncology and Chronic Inflammation)
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop